NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies
Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
Multicenter, open-label study in patients with advanced or metastatic solid tumor
malignancies to evaluate the safety, tolerability, and preliminary anti-tumor efficacy, PK,
and pharmacodynamics of continuously dosed NP-G2-044 monotherapy and NP-G2-044 in combination
with anti-PD-(L)1 therapy.